These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 9560247)
1. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Gualberto A; Aldape K; Kozakiewicz K; Tlsty TD Proc Natl Acad Sci U S A; 1998 Apr; 95(9):5166-71. PubMed ID: 9560247 [TBL] [Abstract][Full Text] [Related]
2. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766 [TBL] [Abstract][Full Text] [Related]
3. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049 [TBL] [Abstract][Full Text] [Related]
4. p53 does not control the spindle assembly cell cycle checkpoint but mediates G1 arrest in response to disruption of microtubule system. Sablina AA; Agapova LS; Chumakov PM; Kopnin BP Cell Biol Int; 1999; 23(5):323-34. PubMed ID: 10579898 [TBL] [Abstract][Full Text] [Related]
5. Gain of function properties of mutant p53 proteins at the mitotic spindle cell cycle checkpoint. Hixon ML; Flores A; Wagner M; Gualberto A Histol Histopathol; 2000 Apr; 15(2):551-6. PubMed ID: 10809376 [TBL] [Abstract][Full Text] [Related]
6. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980 [TBL] [Abstract][Full Text] [Related]
7. The function of a heterozygous p53 mutation in a Li-Fraumeni syndrome patient. Li Y; Li T; Tang Y; Zhan Z; Ding L; Song L; Yu T; Yang Y; Ma J; Zhang Y; Zhou Y; Gu S; Xu M; Gao Y; Li Y PLoS One; 2020; 15(6):e0234262. PubMed ID: 32516327 [TBL] [Abstract][Full Text] [Related]
9. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome. Stein T; Crighton D; Boyle JM; Varley JM; White RJ Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526 [TBL] [Abstract][Full Text] [Related]
10. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Ford JM; Hanawalt PC Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8876-80. PubMed ID: 7568035 [TBL] [Abstract][Full Text] [Related]
11. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome. Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821 [TBL] [Abstract][Full Text] [Related]
12. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family. Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651 [TBL] [Abstract][Full Text] [Related]
13. DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Goi K; Takagi M; Iwata S; Delia D; Asada M; Donghi R; Tsunematsu Y; Nakazawa S; Yamamoto H; Yokota J; Tamura K; Saeki Y; Utsunomiya J; Takahashi T; Ueda R; Ishioka C; Eguchi M; Kamata N; Mizutani S Cancer Res; 1997 May; 57(10):1895-902. PubMed ID: 9157982 [TBL] [Abstract][Full Text] [Related]
14. Allele-specific wild-type TP53 expression in the unaffected carrier parent of children with Li-Fraumeni syndrome. Buzby JS; Williams SA; Schaffer L; Head SR; Nugent DJ Cancer Genet; 2017 Feb; 211():9-17. PubMed ID: 28279309 [TBL] [Abstract][Full Text] [Related]
15. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome. Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881 [TBL] [Abstract][Full Text] [Related]
16. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139 [TBL] [Abstract][Full Text] [Related]
17. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Lang GA; Iwakuma T; Suh YA; Liu G; Rao VA; Parant JM; Valentin-Vega YA; Terzian T; Caldwell LC; Strong LC; El-Naggar AK; Lozano G Cell; 2004 Dec; 119(6):861-72. PubMed ID: 15607981 [TBL] [Abstract][Full Text] [Related]
18. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Evans SC; Lozano G Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689 [TBL] [Abstract][Full Text] [Related]
19. Genetic modeling of Li-Fraumeni syndrome in zebrafish. Parant JM; George SA; Holden JA; Yost HJ Dis Model Mech; 2010; 3(1-2):45-56. PubMed ID: 20075382 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. Capponcelli S; Pedrini E; Cerone MA; Corti V; Fontanesi S; Alessio M; Bachi A; Soddu S; Ribatti D; Picci P; Helman LJ; Cantelli-Forti G; Sangiorgi L Hum Mutat; 2005 Aug; 26(2):94-103. PubMed ID: 15977174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]